Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17268908 | 0.82 | TSHR (0.32) | TSHR | |
| Hydrochloric Acid SCHEMBL17256300 | 0.80 | TSHR (0.31) | TSHR | |
| Trifluoroacetic Acid SCHEMBL17256263 | 0.78 | TSHR (0.39) | TSHRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17934072 | 0.74 | MEN1 (0.39) | TSHR | |
| SCHEMBL25763454 | 0.74 | POLB (0.41) | TSHR | |
| SCHEMBL28887202 | 0.69 | TSHR (0.37) | TSHRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9617040 | 0.69 | — | — | |
| SCHEMBL25764174 | 0.67 | SPHK2 (0.35) | — | |
| SCHEMBL352570 | 0.66 | — | — | |
| SCHEMBL3224210 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391218-B1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9745355-B2 | Binding-site modified lectins and uses thereof | SMARTCELLS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9579391-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9265838-B2 | Conjugate based systems for controlled drug delivery | SMART CELLS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150265717-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9068013-B2 | Recombinant lectins, binding-site modified lectins and uses thereof | SMART CELLS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9050370-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2408470-A1 | Soluble non-depot insulin conjugates and uses thereof | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. | 2011-12-08 | — | — | US | disclosed |
| EP-2391215-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | Smartcells, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2011-11-10 | — | — | US | disclosed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SLC2A4, SLC2A8, CD44 | TSHR 1593/4885SLC1A3 984/4885SLC1A2 1034/4885 |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SI, CSGALNACT1, CD44 | TSHR 1468/4885SLC1A3 474/4885SLC1A2 621/4885 |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | TSHR 292/4885SLC1A3 1393/4885SLC1A2 2145/4885 |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | TSHR 1468/4885SLC1A3 474/4885SLC1A2 621/4885 |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SIGLEC7, SIGLEC9, LGALS3BP | TSHR 2087/4885SLC1A3 1906/4885SLC1A2 2146/4885 |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | TSHR 1468/4885SLC1A3 474/4885SLC1A2 621/4885 |
| US-20160193351-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | TSHR 1468/4885SLC1A3 474/4885SLC1A2 621/4885 |
| US-20150265717-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | TSHR 1468/4885SLC1A3 474/4885SLC1A2 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.